Categories Consumer, Earnings, Retail

Earnings: Adama profit jumps in fourth quarter on strong global demand

Adama Agricultural Solutions, the world leader in off-patent crop protection products, on Wednesday morning, posted its fourth-quarter 2018 results.

Adama gave all its earnings results on an adjusted basis. Revenue increased 17.3% to $963 million, while gross profit for the quarter rose 17.6% to $312 million.

Pre-tax income jumped 279.4% to $47 million, while net income soared 78.6% to $46 million or about $0.019 per diluted share.

“We delivered the strongest fourth-quarter results to date, driving double-digit sales growth over the full year, despite continued subdued agricultural commodity prices and challenging weather conditions in key regions. We continue to strengthen our core business by investing in our pipeline of new and differentiated products, executing on our growth strategy,” weighed in CEO Chen Lichtenstein.

Yang Xingqiang, Chairman of Adama’s Board of Directors, added, “Our robust performance, reaching all-time record highs of nearly $3.9 billion in sales and $653 million in EBITDA, continues to demonstrate our ability to overcome challenging market conditions and grow our market share worldwide. ADAMA’s vast portfolio of differentiated products and global commercial presence enables us to continue our significant growth momentum.”

According to the company, the global crop protection market grew “somewhat” in 2018 due to stronger demand and “normalized inventory levels”, helped by higher procurement costs in China. This was partially offset by challenging weather conditions in Europe, and the uncertainty surrounding US-China trade tensions.

 

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top